Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Moderna (MRNA) announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union, Norway and North ...

Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

We recently published a list of These 10 Firms Were Thursday’s Top Performers. In this article, we are going to take a look ...

Business quiz! Shares of Meta Platforms touched a record high this week after: a) its megabillionaire chief executive Mark ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...